Argenx announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended EC approval of the SC injectable formulation of efgartigimod as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis, or gMG, who are anti acetylcholine receptor, or AChR, antibody positive. SC efgartigimod is formulated with Halozyme’s Enhanze drug delivery technology to facilitate subcutaneous delivery of biologics.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARGX:
- argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
- Argenx price target raised to EUR 560 from EUR 500 at JPMorgan
- Argenx price target raised to $600 from $595 at Piper Sandler
- argenx to Present at Upcoming Investor Conferences
- Argenx price target raised to EUR 500 from EUR 425 at Deutsche Bank
